Literature DB >> 21429904

CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse.

Akiyuki Uzawa, Masahiro Mori, Yasunori Sato, Saeko Masuda, Satoshi Kuwabara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21429904     DOI： 10.1136/jnnp.2011.241760

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  13 in total

Review 1.  Immuno-pathogenesis of neuromyelitis optica and emerging therapies.

Authors:  Norio Chihara; Takashi Yamamura
Journal:  Semin Immunopathol       Date:  2022-05-30       Impact factor: 11.759

Review 2.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

Review 3.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

Review 4.  Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Authors:  Brian G Weinshenker; Gerard Barron; Jacinta M Behne; Jeffery L Bennett; Peter S Chin; Bruce A C Cree; Jerome de Seze; Armando Flor; Kazuo Fujihara; Benjamin Greenberg; Sayumi Higashi; William Holt; Omar Khan; Volker Knappertz; Michael Levy; Angela T Melia; Jacqueline Palace; Terry J Smith; Maria Pia Sormani; Katja Van Herle; Susan VanMeter; Pablo Villoslada; Marc K Walton; Warren Wasiewski; Dean M Wingerchuk; Michael R Yeaman
Journal:  Neurology       Date:  2015-04-03       Impact factor: 9.910

5.  Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases.

Authors:  Livia S Hofer; Sara Mariotto; Sebastian Wurth; Sergio Ferrari; Chiara R Mancinelli; Rachele Delogu; Salvatore Monaco; Alberto Gajofatto; Carmen Schwaiger; Kevin Rostasy; Florian Deisenhammer; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-05-15

6.  Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients.

Authors:  Qianyi He; Lifeng Li; Yanfei Li; Yanhui Lu; Kaimin Wu; Ruiyi Zhang; Junfang Teng; Jie Zhao; Yanjie Jia
Journal:  BMC Neurol       Date:  2019-12-18       Impact factor: 2.474

Review 7.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Authors:  Kazuo Fujihara; Jeffrey L Bennett; Jerome de Seze; Masayuki Haramura; Ingo Kleiter; Brian G Weinshenker; Delene Kang; Tabasum Mughal; Takashi Yamamura
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-08-20

8.  Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate.

Authors:  Ramnath Santosh Ramanathan; Konark Malhotra; Thomas Scott
Journal:  BMC Neurol       Date:  2014-03-15       Impact factor: 2.474

Review 9.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

10.  IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients.

Authors:  Marco Bo; Magdalena Niegowska; Jessica Frau; GianPietro Sechi; Giannina Arru; Eleonora Cocco; Leonardo A Sechi
Journal:  Microorganisms       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.